ClinicalTrials.gg
CompletedNCT01118572Updated Oct 15, 2014

A Study to Verify the Efficacy of YM177 (Celecoxib) in Postoperative Pain Patients

A Phase 3 interventional study of YM177 and etodolac in Post Operative Pain, sponsored by Astellas Pharma Inc. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-10-15.

Sponsored by Astellas Pharma Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
616
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing celecoxib in Pain, Postoperative — 2 open to participants now, 2 under way, none of them phase 3. Celecoxib · Pain, Postoperative.

Enrollment
Largest of 19
616 · median 132
Started
2010
the only one that year
Phase 3
4 of 19
none open now
Registered
4th of 19
by date
Lead sponsor
1 of 19
Astellas Pharma Inc

Among the 19 studies testing celecoxib in Pain, Postoperative, this one has the largest enrollment, is the only one that started in 2010, is one of 4 in phase 3, and was the 4th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

2 of the 19 studies testing celecoxib in Pain, Postoperative are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About celecoxib

Celecoxib: first FDA approval 1998 (CELEBREX), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing celecoxib in Pain, Postoperative, or all of them as a file.
02

Study summary

Aim of the study is to compare efficacy and safety of YM177 with placebo and etodolac in patients with postoperative pain.

Read the detailed description

To verify the superiority to placebo and the noninferiority to etodolac of YM177 in terms of efficacy assessment in patients with postoperative pain. Also, to compare them in terms of safety assessment.

03

Conditions studied

  • Post Operative Pain

Keywords

  • Celecoxib
  • Celecox
  • Pain
  • Surgery
  • NSAIDs
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with spontaneous pain within 24 hours postoperatively
  • The intensity of the pain:

    • 4-categorical assessment: "Moderate pain" or "Severe pain"
    • VAS assessment: 45.0 mm or higher
  • Patients whose postoperative pain can be managed using an oral NSAID

Exclusion criteria

Exclusion Criteria:

  • A past history of aspirin-induced asthma
  • A past of ischemic heart disease, serious arrhythmia, congestive heart failure or cerebrovascular disease
  • Patients who undergoes the surgical procedure under general anesthesia
  • Patients taking excluded medications
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
616 participants (actual)

Study arms

  • Experimental
    YM177 group

    Drug: YM177

  • Active comparator
    etodolac group

    Drug: etodolac

  • Placebo comparator
    placebo group

    Drug: Placebo

Interventions

  • DrugYM177

    oral

    Also known as: Celecoxib, Celecox

  • oral

    Also known as: Osteluc, Hypen

  • DrugPlacebo

    oral

06

What researchers measure

Primary outcomes

  1. Patient impressions (4-categorical assessments)

    Time frame: For 2 days

Secondary outcomes

  1. Pain intensity

    Time frame: For 2 days

  2. Pain intensity difference

    Time frame: For 2 days

  3. Discontinuation due to insufficient efficacy

    Time frame: For 2 days

  4. Safety assessed by AE, clinical lab tests and vital signs

    Time frame: For 2 days

07

Study locations

8 sites
  • Chubu, Japan
  • Chugoku, Japan
  • Hokkaido, Japan
  • Kansai, Japan
  • Kantou, Japan
  • Kyusyu, Japan
  • Shikoku, Japan
  • Touhoku, Japan
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2010, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2010
First posted
May 6, 2010
Start
Feb 2010
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Last update
Oct 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01118572
Responsible party
Sponsor
First posted
May 6, 2010
Start date
Feb 2010
Primary completion
Nov 2010
Completion
Nov 2010
Last update
Oct 15, 2014

Study contacts

Use Central Contact
study chair · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion